CL2024003392A1 - Composiciones farmacéuticas de glp1 - Google Patents
Composiciones farmacéuticas de glp1Info
- Publication number
- CL2024003392A1 CL2024003392A1 CL2024003392A CL2024003392A CL2024003392A1 CL 2024003392 A1 CL2024003392 A1 CL 2024003392A1 CL 2024003392 A CL2024003392 A CL 2024003392A CL 2024003392 A CL2024003392 A CL 2024003392A CL 2024003392 A1 CL2024003392 A1 CL 2024003392A1
- Authority
- CL
- Chile
- Prior art keywords
- glp1
- pharmaceutical compositions
- fluoro
- oxoimi
- dimethyloxan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024003392A1 true CL2024003392A1 (es) | 2025-03-14 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024003392A CL2024003392A1 (es) | 2022-05-11 | 2024-11-06 | Composiciones farmacéuticas de glp1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302809A1 (enExample) |
| EP (1) | EP4522129A1 (enExample) |
| JP (1) | JP7767651B2 (enExample) |
| KR (1) | KR20250002778A (enExample) |
| CN (1) | CN119173255A (enExample) |
| AR (1) | AR129296A1 (enExample) |
| AU (1) | AU2023269995A1 (enExample) |
| CA (1) | CA3253043A1 (enExample) |
| CL (1) | CL2024003392A1 (enExample) |
| CO (1) | CO2024015285A2 (enExample) |
| DO (1) | DOP2024000232A (enExample) |
| IL (1) | IL316629A (enExample) |
| MX (1) | MX2024013839A (enExample) |
| PE (1) | PE20251285A1 (enExample) |
| TW (2) | TW202508581A (enExample) |
| WO (1) | WO2023220109A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| WO2002064132A2 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CN101511184A (zh) * | 2006-09-08 | 2009-08-19 | 默克公司 | 用于口服给药cgrp拮抗剂的液体药物制剂 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| CN120284862A (zh) * | 2018-12-07 | 2025-07-11 | 纽罗克里生物科学有限公司 | 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式 |
| UY38696A (es) * | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| KR20230066379A (ko) * | 2020-09-09 | 2023-05-15 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 제형 |
| US20250325525A1 (en) * | 2022-05-11 | 2025-10-23 | Eli Lilly And Company | Glp1 tablet compositions |
-
2023
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
-
2024
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI867526B (zh) | 2024-12-21 |
| MX2024013839A (es) | 2024-12-06 |
| KR20250002778A (ko) | 2025-01-07 |
| WO2023220109A1 (en) | 2023-11-16 |
| EP4522129A1 (en) | 2025-03-19 |
| TW202410894A (zh) | 2024-03-16 |
| CA3253043A1 (en) | 2023-11-16 |
| PE20251285A1 (es) | 2025-05-14 |
| CO2024015285A2 (es) | 2024-11-28 |
| TW202508581A (zh) | 2025-03-01 |
| AR129296A1 (es) | 2024-08-07 |
| CN119173255A (zh) | 2024-12-20 |
| IL316629A (en) | 2024-12-01 |
| AU2023269995A1 (en) | 2024-11-14 |
| JP2025515706A (ja) | 2025-05-20 |
| JP7767651B2 (ja) | 2025-11-11 |
| US20250302809A1 (en) | 2025-10-02 |
| DOP2024000232A (es) | 2024-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024003392A1 (es) | Composiciones farmacéuticas de glp1 | |
| Ellepola et al. | Oral candidal infections and antimycotics | |
| DOP2024000235A (es) | Composiciones de comprimidos de glp1 | |
| MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| MA52424B1 (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| UA93496C2 (uk) | Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу | |
| MA27624A1 (fr) | Procede pour realiser une preparation enrobee | |
| BE1005808A5 (fr) | Medicaments pour traiter les troubles gastro-intestinaux. | |
| MA42946B1 (fr) | Sels et formes solides d'un antibiotique de type monobactame | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| NZ776354A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| DE69518237D1 (de) | Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff | |
| CH683068A5 (fr) | Compositions pharmaceutiques contenant des dérivés de furanne. | |
| JP2015536949A (ja) | 細菌感染症のための抗生物質を用いる方法および組成物 | |
| MX2021014944A (es) | Metodos para tratar cancer usando inhibidores de prmt5. | |
| MA30691B1 (fr) | Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. | |
| CL2025001273A1 (es) | Compuesto bicíclico fusionado | |
| MA62176A1 (fr) | Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène | |
| US20200405687A1 (en) | Methods for the treatment of infection | |
| EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
| WO2022115681A3 (en) | Methods and compositions for oral pilocarpine liquid | |
| MA29567B1 (fr) | (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one |